Fate Of AstraZeneca's Iressa To Be Discussed By Advisory Cmte. March 4

FDA will seek input from its Oncologic Drugs Advisory Committee on whether Iressa's accelerated approval should be withdrawn after the non-small cell lung cancer agent failed to show a survival benefit in a confirmatory trial.